BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...Matterhorn Biosciences AG and McMaster University spinout Triumvira Immunologics Inc., have...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

...therapy investments include T cell immunotherapy company Triumvira Immunologics Inc....
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...solid tumors helped drive investor interest By Paul Bonanos, Associate Editor Since its 2015 launch, Triumvira...
...Ventures led the round, which will support clinical development of two cell therapies based on Triumvira Immunologics Inc.’s...
...early-stage platform technologies.“Our investors see that our value proposition is in the solid tumor setting,” Triumvira...
BioCentury | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

...VP of development operations of eFFECTOR Therapeutics Inc. (San Diego, Calif.) T cell therapy company Triumvira Immunologics Inc....
BioCentury | Jun 11, 2018
Company News

Management tracks: Arbutus, Cancer Research UK

...SVP and CFO. He was EVP and CFO at Sosei Group Corp. (Tokyo:4565). Immunotherapy company Triumvira Immunologics Inc....
BioCentury | May 18, 2018
Company News

Management tracks: Seattle Genetics, SurModics

...development leader within the diabetes business unit. at Eli Lilly and Co. (NYSE:LLY). Immunotherapy company Triumvira Immunologics Inc....
BioCentury | Aug 15, 2017
Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

...Inc. (NASDAQ:IMNP; SSE:IMNP) named Tony Fiorino CMO and COO. He was president and CEO at Triumvira Immunologics Inc....
BioCentury | Dec 2, 2016
Emerging Company Profile

Passing CARs

...produced profound responses in hematological cancers, but also severe toxicities such as cytokine release syndrome. Triumvira Immunologics Inc....
...to a T cell, whereas a CAR functions more as an on switch,” he said. Triumvira...
...TAC in multiple myeloma. Triumvira also has TACs targeting undisclosed solid tumor antigens in discovery. Triumvira...
Items per page:
1 - 8 of 8
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...Matterhorn Biosciences AG and McMaster University spinout Triumvira Immunologics Inc., have...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

...therapy investments include T cell immunotherapy company Triumvira Immunologics Inc....
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...solid tumors helped drive investor interest By Paul Bonanos, Associate Editor Since its 2015 launch, Triumvira...
...Ventures led the round, which will support clinical development of two cell therapies based on Triumvira Immunologics Inc.’s...
...early-stage platform technologies.“Our investors see that our value proposition is in the solid tumor setting,” Triumvira...
BioCentury | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

...VP of development operations of eFFECTOR Therapeutics Inc. (San Diego, Calif.) T cell therapy company Triumvira Immunologics Inc....
BioCentury | Jun 11, 2018
Company News

Management tracks: Arbutus, Cancer Research UK

...SVP and CFO. He was EVP and CFO at Sosei Group Corp. (Tokyo:4565). Immunotherapy company Triumvira Immunologics Inc....
BioCentury | May 18, 2018
Company News

Management tracks: Seattle Genetics, SurModics

...development leader within the diabetes business unit. at Eli Lilly and Co. (NYSE:LLY). Immunotherapy company Triumvira Immunologics Inc....
BioCentury | Aug 15, 2017
Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

...Inc. (NASDAQ:IMNP; SSE:IMNP) named Tony Fiorino CMO and COO. He was president and CEO at Triumvira Immunologics Inc....
BioCentury | Dec 2, 2016
Emerging Company Profile

Passing CARs

...produced profound responses in hematological cancers, but also severe toxicities such as cytokine release syndrome. Triumvira Immunologics Inc....
...to a T cell, whereas a CAR functions more as an on switch,” he said. Triumvira...
...TAC in multiple myeloma. Triumvira also has TACs targeting undisclosed solid tumor antigens in discovery. Triumvira...
Items per page:
1 - 8 of 8